An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism

Author:

Takacs Istvan1ORCID,Mezosi Emese2ORCID,Soto Alfonso3ORCID,Kamenický Peter4ORCID,Figueres Lucile5ORCID,Galvez Moreno Maria Angeles6ORCID,Lemoine Sandrine7ORCID,Borson-Chazot Francoise8ORCID,Capel Ismael9ORCID,Ouldrouis Taha10ORCID,Lucas Nadège10ORCID,Allas Soraya10ORCID,Sumeray Mark10ORCID,Ovize Michel10ORCID,Mannstadt Michael11ORCID

Affiliation:

1. Department of Internal Medicine and Oncology, Semmelweis University , 1088 Budapest , Hungary

2. Department of Endocrinology, Pecsi Tudomanyegyetem , 7623 Pecs , Hungary

3. Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario A Coruña , 15006 Coruña , Spain

4. Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate, Université Paris-Saclay, Inserm , 94270 Le Kremlin Bicêtre , France

5. Department of Nephrology and Clinical Immunology, Centre Hospitalier Universitaire Nantes-Université de Nantes , 44093 Nantes , France

6. Department of Endocrinology and Nutrition, Hospital Universitario Reina Sofía , 14004 Cordoba , Spain

7. Department of Nephrologie, Hypertension-dialysis, Hospices Civils de Lyon and Claude Bernard University , 69008 Lyon , France

8. Department of Endocrinology, Diabetes and Metabolic Diseases, Hospices Civils de Lyon and Claude Bernard University , 69394 Lyon , France

9. Department of Endocrinology and Nutrition, Parc Tauli University Hospital , 08208 Sabadell, Barcelona , Spain

10. Amolyt Pharma , 69130 Ecully , France

11. Endocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School , Boston, MA 02114 , USA

Abstract

Abstract Context Hypoparathyroidism is a rare disorder characterized by a deficiency in PTH resulting in hypocalcemia, hyperphosphatemia, and hypercalciuria. Eneboparatide is an investigational peptide agonist of the PTH1 receptor for the treatment of chronic hypoparathyroidism (HP). Objective To evaluate the efficacy, safety, and tolerability of eneboparatide in HP patients. Design Open-label, phase 2 study. Participants Twenty-eight patients (21 women, 7 men), mean age (range): 58 years (28-72), with HP were enrolled into 2 consecutive cohorts (C1, n = 12 and C2, n = 16). Intervention Following an optimization period, daily subcutaneous injections of eneboparatide were administered for 3 months at a 20 µg/day (C1) or 10 µg/day (C2) starting dose. Conventional therapy was progressively removed, and eneboparatide could be titrated up to 60 µg (C1) or 80 µg (C2). Main outcomes Proportion of patients achieving independence from conventional therapy, albumin-adjusted serum calcium (ADsCa), 24-h urine calcium (uCa), serum bone turnover markers (serum carboxy-terminal telopeptide of type I collagen and procollagen 1 intact N-terminal propeptide), bone mineral density (BMD), and adverse events (AEs). Results After 3 months, ≥ 88% of patients achieved independence from conventional therapy while mean ADsCa was maintained within target range (7.8-9 mg/dL). Eneboparatide induced a rapid and sustained reduction of mean 24-hour uCa, even among patients with hypercalciuria. Bone turnover markers slightly increased, and BMD remained unchanged, consistent with progressive resumption of physiologic bone turnover. Eneboparatide was well tolerated with no serious AEs. Conclusion Eneboparatide allowed independence from conventional therapy and maintenance of serum calcium within a target range while normalizing uCa excretion and producing a balanced resumption of bone turnover.

Funder

Amolyt Pharma, France

Publisher

The Endocrine Society

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Hypoparathyroidism update;Current Opinion in Endocrinology, Diabetes & Obesity;2024-05-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3